ACESOT-1051 Trial Expanded to Include HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) Patients, Targeting Populations Most Likely to Benefit for WEEI InhibitionDOYLESTOWN, Pa., March 31, 2025 ...

Immunotherapy for HPV+ head and neck cancer: Awakening the force within T cell targets present in tumors Date: September 1, 2021 Source: Emory Health Sciences Summary: The immune cells that are ...

HPV-driven cancers, including HPV+ HNSCC, are particularly susceptible to this treatment due to defects in their DNA damage repair pathways. Aprea is focusing on identifying patient populations ...

When I learned I had Stage 4 HPV-related oral cancer, I didn’t know exactly what it meant, but I knew there wasn’t a Stage 5.

Preclinical and clinical data show promise for APR-1051 in treating HPV+ head and neck cancer, highlighting efficacy and safety. Quiver AI Summary Aprea Therapeutics announced promising ...

The group's pre-clinical research in cell lines and mouse models of HPV+ cancers shows that fenofibrate performed as well against these cancers as the conventional chemotherapy drug cisplatin ...

SQZ Biotechnologies Announces FDA Clearance of IND Application to Allow for Clinical Trial with SQZ Activating Antigen Carriers (SQZ AACs) in Patients with HPV+ Tumors ...

PRESS RELEASE EnnoDC presents preliminary data for immunotherapy candidate CD40.HVac in HPV+ oropharyngeal cancer at ESMO IO 2024 Paris, France, 9 December 2024 – EnnoDC, a clinical-stage ...

The Phase 1b portion of the CUE-101 monotherapy clinical trial in patients with HPV+ second line and beyond (2L+) head and neck squamous cell carcinoma (HNSCC) is expected to enroll up to 20 ...

ACESOT-1051 Trial Expanded to Include HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) Patients, Targeting Populations Most Likely to Benefit for WEEI InhibitionDOYLESTOWN, Pa., March 31, 2025 ...